[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE500836T1 - Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung - Google Patents

Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung

Info

Publication number
ATE500836T1
ATE500836T1 AT05732325T AT05732325T ATE500836T1 AT E500836 T1 ATE500836 T1 AT E500836T1 AT 05732325 T AT05732325 T AT 05732325T AT 05732325 T AT05732325 T AT 05732325T AT E500836 T1 ATE500836 T1 AT E500836T1
Authority
AT
Austria
Prior art keywords
adrenomedullin
ischemia
binding protein
mammal
reperfusion treatment
Prior art date
Application number
AT05732325T
Other languages
English (en)
Inventor
Ping Wang
Original Assignee
The Feinstein Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Feinstein Inst Medical Res filed Critical The Feinstein Inst Medical Res
Application granted granted Critical
Publication of ATE500836T1 publication Critical patent/ATE500836T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT05732325T 2004-03-31 2005-03-30 Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung ATE500836T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55793504P 2004-03-31 2004-03-31
PCT/US2005/010822 WO2005097172A2 (en) 2004-03-31 2005-03-30 Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment

Publications (1)

Publication Number Publication Date
ATE500836T1 true ATE500836T1 (de) 2011-03-15

Family

ID=35125617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732325T ATE500836T1 (de) 2004-03-31 2005-03-30 Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung

Country Status (8)

Country Link
US (1) US9101593B2 (de)
EP (1) EP1742651B1 (de)
JP (1) JP4914344B2 (de)
AT (1) ATE500836T1 (de)
AU (1) AU2005231395B2 (de)
CA (1) CA2562957C (de)
DE (1) DE602005026794D1 (de)
WO (1) WO2005097172A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742651B1 (de) 2004-03-31 2011-03-09 The Feinstein Institute for Medical Research Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
US8703693B2 (en) 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
JP4830093B2 (ja) * 2005-04-08 2011-12-07 国立大学法人 宮崎大学 非細菌性の炎症性疾患の予防又は治療剤
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
GB9624731D0 (en) 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
US6620615B1 (en) * 1999-04-23 2003-09-16 Curagen Corporation G-protein coupled receptor—encoding nucleic acids
EP1214600B1 (de) 1999-09-10 2005-12-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Bestimmung von adrenomedullin-bindenden proteinen
US6864237B2 (en) * 2002-05-17 2005-03-08 Ping Wang Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
US6884781B2 (en) 2003-05-16 2005-04-26 Ping Wang Treatment of shock using adrenomedullin binding protein-1
US20080051315A1 (en) 2003-12-11 2008-02-28 Eric Kandel Grp Receptor-Related Methods for the Treating and Preventing Fear-Related Disorders
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1742651B1 (de) 2004-03-31 2011-03-09 The Feinstein Institute for Medical Research Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
US9107917B2 (en) 2005-05-13 2015-08-18 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2A adrenergic antagonists
CN101203234B (zh) 2005-05-13 2012-10-10 范斯坦医药研究院 乳脂小球表皮生长因子-因子ⅷ和脓毒病
EP2215264B1 (de) 2007-11-15 2015-04-01 The Feinstein Institute for Medical Research Vorbeugung und behandlung von entzündung und organverletzung nach ischämie/reperfusion unter verwendung von mfg-e8
US8324151B2 (en) 2007-11-20 2012-12-04 The Feinstein Institute For Medical Research Treatment of sepsis and septic shock using ghrelin and growth hormone

Also Published As

Publication number Publication date
WO2005097172A2 (en) 2005-10-20
EP1742651A2 (de) 2007-01-17
EP1742651A4 (de) 2009-08-05
US20140342988A1 (en) 2014-11-20
AU2005231395A1 (en) 2005-10-20
CA2562957A1 (en) 2005-10-20
AU2005231395B2 (en) 2011-06-16
US9101593B2 (en) 2015-08-11
JP4914344B2 (ja) 2012-04-11
WO2005097172A3 (en) 2006-03-30
DE602005026794D1 (de) 2011-04-21
CA2562957C (en) 2013-05-21
JP2007537160A (ja) 2007-12-20
EP1742651B1 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
NO20054988D0 (no) Preparater og metoder for behandling av cancer
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
PT2601961T (pt) Composições compreendendo lag-3 e anticorpos terapêuticos e as suas utilizações no tratamento de cancro
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
EP2118123A4 (de) Stabilisierte p53-peptide und deren verwendungen
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
IL185491A0 (en) Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
WO2009079585A3 (en) Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
EP2012798A4 (de) Verwendung von inositol-tripyrophosphat bei der behandlung von tumoren und erkrankungen
GB0426255D0 (en) Improvements in and relating to products for skin treatment
DE602005015439D1 (de) Intravitreale implantate in verbindung mit photodynamischer therapie zur verbesserung der sehkraft
ATE500836T1 (de) Adrenomedullin und adrenomedullin-bindungsprotein zur ischämie/reperfusionsbehandlung
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.
EP1696933A4 (de) Zusammensetzungen und verfahren zur verabreichung von tubulin-bindenden mitteln zur behandlung von augenkrankheiten
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
ATE511401T1 (de) Kombinierte gentherapie zur behandlung makroskopischer glioma
HK1118007A1 (en) Kim-1 antibodies for treatment of th2-mediated conditions
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
EP1773363A4 (de) Ngna-zusammensetzungen und anwendungsverfahren
EP1973398A4 (de) Verwendung von inosit-tripyrophosphat bei der behandlung von tumoren und krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties